Scholar Rock Holding shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 71 to 82.

Scholar Rock's second quarter saw the relatively early-stage company post no revenue and a net loss of over $110 million, or $0.98 per share. This was far steeper than the nearly $59 deficit in the ...

An analyst initiated coverage of the healthcare stock. He's flagged it as a buy at the current price. Well before market open, Leerink Partners' Mani Foroohar launched his coverage of Scholar Rock, ...

Scholar Rock (SRRK) stock's buy rating reiterated with $97 target on rising apitegromab approval odds; phase 3 data broadens ...

A third-party manufacturing facility has apparently been flagged by the FDA. The plant is owned by pharmaceutical industry peer Novo Nordisk. In a tersely worded post on its website, Scholar Rock ...

Well before market open, Leerink Partners' Mani Foroohar launched his coverage of Scholar Rock, rating the healthcare stock as an outperform (i.e., buy) at a price target of $51 per share. That ...